Patient selection and baseline information
dysplasia, ONFH, MP, fatigue
OSTEONECROSIS OF THE FEMORAL HEAD, SECONDARY, DYSPLASIA, OSTEOARTHRITIS
Out of 89 consecutively screened patients, a final cohort of 80 was selected for participation in this study, following a six-month follow-up period and the application of exclusion criteria that removed 8 individuals. A further individual declined to participate. Of the remaining patients, 40 were allocated to the TXA group, while the remaining 40 were assigned to the MP + TXA group. Both primary and secondary outcomes were fully tracked over the follow-up period. Comparative baseline characteristics for both groups are provided in Table Baseline informationMP: Methylprednisolone; TXA: Tranexamic acid; n: number; CRP: C-reactive protein; IL-6: interleukin 6; Hb: Hemoglobin; Hct: Hematocrit; BMI: Body mass index; ICFS: Identity consequence fatigue scale; ASA: America anesthesia association; OA: Osteoarthritis; ONFH: Osteonecrosis of the femoral head; DDH: Development dysplasia hip; ROM: Range of motion; VAS: Visual analog scale; ASA: America anesthesia association; APTT: Activated partial thromboplastin time; y: Years; Pre-: PreoperativeCONSORT flow diagram. MP: Methylprednisolone; TXA: Tranexamic acid